ProStrakan submits Abstral NDA

Orexo AB (SSE:ORX) said partner ProStrakan Group plc (LSE:PSK) submitted an NDA to FDA for Abstral to treat breakthrough cancer pain, triggering an undisclosed milestone to Orexo. ProStrakan has right...